| India | Turkey | Austria | |
| Immunotherapy with Keytruda (Pembolizumab) | from $3,500 | from $3,300 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy with Keytruda (Pembolizumab) upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy with Keytruda (Pembolizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy with Keytruda (Pembolizumab) journey.
Dr. Ahmer Arif Shaikh specializes in oral cancer treatment and functional rehabilitation at HCG Manavata Cancer Centre.
Dr. Chaitainya Borde has performed over 30,000 PET scans and treated 1,000+ thyroid cancer patients at HCG Manavata Cancer Centre.
30 years of experience of surgical oncology experience – Dr. Nagarkar has performed over 50,000 cancer surgeries at HCG Manavata Cancer Centre.
Dr. Girish Badarkhe specializes in treating blood cancers with immunotherapy at HCG Manavata Cancer Centre, offering 16 years of experience of focused expertise.
Keytruda, a form of immune-based therapy, leverages the body's immune system to target and destroy cancer cells using monoclonal antibodies.
Keytruda is an immunotherapy medication that reboots the immune system to identify and kill cancer cells. Unlike chemotherapy, this monoclonal antibody blocks the PD-1 pathway, preventing tumors from hiding and allowing T cells to naturally destroy advanced cancers like melanoma or lung carcinoma.
Bookimed Expert Insight: India has become a global hub for Keytruda due to high-volume expertise at centers like HCG Manavata Cancer Centre, where teams have performed over 50,000 surgeries. While US infusions average $21,500, Indian clinics offer the same immunotherapy starting at $3,500, saving patients up to 77%.
Patient Consensus: Patients emphasize that immunotherapy feels different from chemotherapy because it revs up immunity rather than poisoning cells. many report that monitoring biomarkers like PD-L1 was crucial for predicting their individual success with the drug.
Keytruda is approved in India by the Drug Controller General of India (DCGI). It is cleared for multiple cancer indications including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Treatment is available at JCI-accredited facilities like Artemis Hospitals and Apollo Hospital Indraprastha.
Bookimed Expert Insight: Success with Keytruda in India often depends on doctor experience with immunotherapy protocols. Dr. Shruti Kate at HCG Manavata Cancer Centre specializes specifically in these treatments. Many top Indian clinics now also use IBM Watson AI platforms to verify treatment compatibility.
Patient Consensus: Success depends on confirming drug availability for your specific cancer subtype before traveling. Patients highly value the cost difference but recommend asking about immune-related side effect monitoring plans.